Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 24, 2024 - Issue 7: Biosimilars 2024
Submit an article Journal homepage
275
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Relative bioavailability, immunogenicity, and safety of two adalimumab-adbm formulations in healthy volunteers: a double-blind, randomized, single-dose, parallel-arm Phase I trial (VOLTAIRE-HCLF)

Viktoria Moschettia Global Clinical Development & Operations, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, GermanyCorrespondence[email protected]
View further author information
,
Susanne Buschkeb Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach/Riss, GermanyView further author information
,
Julia Bertulisb Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach/Riss, GermanyView further author information
,
Kathrin Hohlb Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach/Riss, GermanyView further author information
&
Dorothy McCabec Specialty Medicine, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USAView further author information
Pages 673-679 | Received 12 Jan 2024, Accepted 09 May 2024, Published online: 19 May 2024

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

Order Reprints Request Permissions

For more information please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.